Starling Oncology, Inc. (STLN) Balance Sheet
As of 2026-06-30 (10-Q), Starling Oncology, Inc. (STLN) reported total assets of $178.2M, total liabilities of $203.1M and shareholders' equity of -$24.9M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $41.1M. Long-term debt: $79.9M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
STLNStarling Oncology, Inc.Follow STLN — free
—
Price chart with a free account
- Market cap
- 683.9M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
| Line | FY2020 Mar 20 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | — | 6.0 | 115.2 | 14.0 | 33.5 | 49.7 | 33.6 | 41.1 | |
| Short-term investments | — | — | 0.0 | 59.8 | 49.4 | 0.0 | — | — | |
| Receivables | — | 17.1 | 20.0 | 39.8 | 42.4 | 48.3 | 59.0 | 66.3 | |
| Inventory | — | 4.4 | 6.4 | 9.3 | 13.7 | 10.0 | 16.9 | 20.0 | |
| Current assets | — | 29.7 | 154.1 | 130.4 | 143.5 | 112.4 | 112.7 | 129.0 | |
| Total assets | 231.8 | 65.7 | 203.4 | 261.7 | 209.2 | 172.7 | 164.7 | 178.2 | |
| Current liabilities | — | 28.6 | 29.8 | 29.7 | 34.8 | 52.2 | 71.0 | 94.9 | |
| Long-term debt | — | 6.6 | 0.0 | 80.6 | 86.8 | 93.1 | 77.4 | 79.9 | |
| Short-term debt | — | 5.4 | 0.2 | 0.0 | — | — | — | — | |
| Total liabilities | 17.8 | 37.6 | 99.3 | 138.5 | 152.2 | 169.1 | 180.4 | 203.1 | |
| Shareholders' equity | -16.0 | 28.1 | 104.2 | 123.2 | 57.0 | 3.6 | -15.7 | -24.9 |
USD millions · SEC XBRL
Starling Oncology, Inc. — questions
- How much cash does Starling Oncology, Inc. have?
- $41.1M in cash and cash equivalents as of 2026-06-30.
- How much debt does Starling Oncology, Inc. have?
- $79.9M of long-term debt as of 2026-06-30.
- What are Starling Oncology, Inc.'s total assets?
- $178.2M as of 2026-06-30.
- What is Starling Oncology, Inc.'s shareholders' equity?
- -$24.9M as of 2026-06-30.
Every figure on this page comes from Starling Oncology, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.